HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease.

AbstractBACKGROUND AND PURPOSE:
To assess the long-term safety and efficacy of pramipexole as a once-daily (q.d.) extended-release oral formulation in early or advanced Parkinson's disease (PD).
METHODS:
In two double-blind (DB) studies of early PD and one of advanced PD,active-treatment arms received pramipexole immediate release (IR) or extended release (ER), with exposure lasting up to 33 weeks. In open-label (OL) extensions that followed immediately, subjects took ER q.d. for up to 80 weeks, with dosage adjustment permitted (range 0.375-4.5 mg q.d.).
RESULTS:
Of 590 subjects completing an early-PD DB study, 511 entered the early-PD OL extension; 408 completed it. Reported adverse events (AEs) with incidence ≥10.0% were somnolence (15.1%), peripheral edema (11.7%) and back pain (10.6%). Of 465 subjects completing the advanced-PD DB study, 391 entered the advanced-PD OL extension; 329 completed it. Reported AEs with incidence ≥10.0%were dyskinesia (27.4%) and somnolence (13.6%). Impulse control disorders were identified by semi-structured interview in 13 subjects (1.4% of 902). In exploratory analyses, adjusted mean Unified Parkinson's Disease Rating Scale (UPDRS) PartsII + III scores (excluding ex-placebo recipients) remained substantially improved from DB baseline scores prior to pramipexole introduction, at -6.6 and -6.3 points amongst ex-DB-ER and ex-DB-IR recipients after 113 weeks of pramipexole (33 DB plus 80 OL) in early PD, and -11.5 and -9.1 after up to 113 weeks (up to 33 DB plus 80 OL) in advanced PD.
CONCLUSIONS:
These results support the long-term safety and efficacy of pramipexole ER in early and advanced PD. AEs were typical for dopaminergic medications, and UPDRS scores suggested sustained symptomatic benefit.
AuthorsR A Hauser, A H V Schapira, P Barone, Y Mizuno, O Rascol, M Busse, C Debieuvre, M Fraessdorf, W Poewe,
JournalEuropean journal of neurology (Eur J Neurol) Vol. 21 Issue 5 Pg. 736-43 (May 2014) ISSN: 1468-1331 [Electronic] England
PMID24834511 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antiparkinson Agents
  • Benzothiazoles
  • pramipexole
Topics
  • Aged
  • Antiparkinson Agents (therapeutic use)
  • Benzothiazoles (therapeutic use)
  • Disorders of Excessive Somnolence (etiology)
  • Disruptive, Impulse Control, and Conduct Disorders (chemically induced)
  • Double-Blind Method
  • Drug Administration Schedule
  • Drug Delivery Systems (adverse effects, methods)
  • Dyskinesia, Drug-Induced (etiology)
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Parkinson Disease (drug therapy)
  • Severity of Illness Index
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: